Lilly, Amylin, Alkermes Shares Get Crushed After FDA Rejects Diabetes Drug
Shares of pharmaceutical companies Amylin, Alkermes, and Eli Lilly — partners in a new diabetes drug Bydureon — have tanked in morning trading as the U.S. Food and Drug Administration declined on Tuesday to approve the drug w…